Ghiselli Roberto, Giacometti Andrea, Cirioni Oscar, Mocchegiani Federico, Orlando Fiorenza, Silvestri Carmela, Di Matteo Fabio, Abbruzzetti Alessandra, Scalise Giorgio, Saba Vittorio
Department of General Surgery, INRCA-IRRCS, Università Politecnica delle Marche, Ancona, Italy.
Crit Care Med. 2008 Jan;36(1):240-5. doi: 10.1097/01.CCM.0000292157.60632.89.
To investigate the efficacy of piperacillin/tazobactam combined with indolicidin in the prevention of lethality in two rat models of polymicrobial peritonitis.
Prospective, randomized, controlled animal study.
Research laboratory in a university hospital.
Adult male Wistar rats.
Adult male Wistar rats were given an intraperitoneal injection of 1 mg of Escherichia coli 0111:B4 lipopolysaccharide or had intraabdominal sepsis induced by cecal ligation and puncture. For each model, all animals were randomized to receive isotonic sodium chloride solution intraperitoneally, 1 mg/kg indolicidin, 120 mg/kg piperacillin/tazobactam, and 1 mg/kg indolicidin combined with 120 mg/kg piperacillin/tazobactam. Each group included 20 animals.
Main outcome measures were: bacterial growth in blood, peritoneum, spleen, liver, and mesenteric lymph nodes; endotoxin, interleukin-6, and tumor necrosis factor-alpha concentrations in plasma; and lethality. All compounds reduced significantly bacterial growth and lethality compared with saline treatment. Treatment with indolicidin resulted in significant decrease in plasma endotoxin and cytokine levels, whereas piperacillin/tazobactam exerted the opposite effect. The combination between indolicidin and piperacillin/tazobactam proved to be the most effective treatment in reducing all variables measured.
Indolicidin may have potential therapeutic usefulness alone and when associated with piperacillin/tazobactam in polymicrobial peritonitis.
研究哌拉西林/他唑巴坦联合吲哚杀菌素在两种多微生物性腹膜炎大鼠模型中预防致死率的疗效。
前瞻性、随机、对照动物研究。
大学医院的研究实验室。
成年雄性Wistar大鼠。
成年雄性Wistar大鼠腹腔注射1毫克大肠杆菌0111:B4脂多糖,或通过盲肠结扎和穿刺诱导腹腔感染。对于每种模型,所有动物随机分为腹腔注射等渗氯化钠溶液、1毫克/千克吲哚杀菌素、120毫克/千克哌拉西林/他唑巴坦,以及1毫克/千克吲哚杀菌素联合120毫克/千克哌拉西林/他唑巴坦。每组包括20只动物。
主要观察指标为:血液、腹膜、脾脏、肝脏和肠系膜淋巴结中的细菌生长;血浆中的内毒素、白细胞介素-6和肿瘤坏死因子-α浓度;以及致死率。与生理盐水治疗相比,所有化合物均显著降低了细菌生长和致死率。吲哚杀菌素治疗导致血浆内毒素和细胞因子水平显著降低,而哌拉西林/他唑巴坦则产生相反的效果。吲哚杀菌素与哌拉西林/他唑巴坦联合使用被证明是降低所有测量变量最有效的治疗方法。
吲哚杀菌素单独使用以及与哌拉西林/他唑巴坦联合使用时,在多微生物性腹膜炎中可能具有潜在的治疗作用。